SVS:CA

Solarvest Launches World's First Organic DHA Omega-3 Fruit Gummy Drops for Children

(TheNewswire)



TheNewswire - December 21 st, 2020  -  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), Solarvest, through it's 100% wholly owned subsidiary Eversea TM is pleased to announce plans to launch its Organic Omega-3 nutritional Gummy Fruit Drops for children after the year-end holiday break.  The fruit drop has been produced and passed quality control under high standards from our German contract manufacturer.  The final phase is to confirm the quality of the product after the logistics of shipping and packaging which is underway.  The Company's first of its kind nutritional gummy product will be an exceptional competitor in the large and rapidly growing gummy supplement market.  The organic gummy contains Solarvest's proprietary, certified organic, Omega-3 DHA powder, a sustainable, plant based powder designed for organic, vegetarian and vegan consumers.

The Company is actively working to add unique products to satisfy the demand for premium organic, Omega-3 and plant-based health products.  This first labelled product will soon commence sales in the USA and be available from the company's E-commerce web site ( www.eversea.ca ) and through Amazon. Eversea will be capable of providing organic oriented retailers with house branded products based on our patented ingredient (differentiation), so that they may take benefit from the extensive market demand for the product's unique characteristics, particularly for organic and vegan diets.

The company also announces the completion of its USA infrastructure and logistics system for order processing. Our west coast distribution point is located close to the primary and most important market for organic and plant based supplements/foods.  In addition this strategic location is close to organic food processors, sustainable oriented consumers and the organic baby food market.  The facility is capable of nation-wide distribution.

The Eversea Omega-3 powder is USDA and EU Organic Certified and produced from the Company's sustainable, proprietary process.  Gerri Greenham, CEO, notes that, "Our omega 3's are sustainable because they are expressed in algae and grown in controlled facilities which eliminates the need to harvest marine species.  Our technology produces an organically certified, highly bioavailable long-chain Omega-3 that cannot be produced by common plant species such as flaxseed or hemp which only contain ALA Omega-3.  Our customers are buying a product to improve health so they want an organic product which has a clean label of ingredients."  The Company also intends to sell the powder supplement to organic food processors and marketers, such as baby food suppliers, to facilitate the development of enhanced patent-protected products. The Company also intends to pursue other premium animal health applications such as high Omega-3 eggs, pet supplements and food. "

Eversea has also initiated a second product run with its German-based organically certified manufacturer to supplement inventory levels domestically and initiate international sales. Recognizing that Eversea's organically certified product holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, the Company will be able to deliver alternatives for the adult, seniors, infant formula and maternity markets to complement its adolescent offering.

Market Overview

"The EPA and DHA omega-3 finished product market size reached US$44.2 billion in 2019. as stated in the  2020 Global EPA &DHA Finished Goods Report.  Market dynamics and new product development are driving increased growth in certain product categories and across several regions of the world, leading the global EPA and DHA consumer product market to a projected annual growth rate of 6.1% for 2020–2021".

"The global gummy vitamins market size is estimated to be valued at USD 5.9 billion in 2020 and projected to reach USD 10.6 billion by 2025, recording a CAGR of 12.5%, in terms of value" as stated by Reportlinker in Oct 27, 2020 PRNewswirepress release.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2020 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation
maintained throughout the 26-week study

Episodes of pericarditis per year substantially reduced

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×